1. Home
  2. ROIV vs DGX Comparison

ROIV vs DGX Comparison

Compare ROIV & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$35.36

Market Cap

26.2B

Sector

Health Care

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$238.40

Market Cap

23.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
DGX
Founded
2014
1967
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.2B
23.2B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
ROIV
DGX
Price
$35.36
$238.40
Analyst Decision
Strong Buy
Buy
Analyst Count
9
13
Target Price
$28.94
$214.38
AVG Volume (30 Days)
4.8M
1.0M
Earning Date
05-28-2026
04-21-2026
Dividend Yield
N/A
1.82%
EPS Growth
N/A
13.78
EPS
N/A
5.08
Revenue
$8,260,000.00
$11,035,000,000.00
Revenue This Year
N/A
$7.53
Revenue Next Year
$744.61
$3.77
P/E Ratio
N/A
$46.63
Revenue Growth
N/A
11.78
52 Week Low
$11.54
$171.18
52 Week High
$37.00
$240.13

Technical Indicators

Market Signals
Indicator
ROIV
DGX
Relative Strength Index (RSI) 54.80 72.83
Support Level $33.01 $188.53
Resistance Level $36.35 $240.13
Average True Range (ATR) 1.26 5.84
MACD 0.04 0.33
Stochastic Oscillator 63.92 88.92

Price Performance

Historical Comparison
ROIV
DGX

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: